Chimeric Defensin Proteins for Cancer Vaccines

Available for licensing is a fusion protein vaccine comprising a defensin peptide fused to a tumor antigen to elicit an immune response effective in treating cancer.

Humans are particularly vulnerable to cancer as a result of an ineffective immunogenic response. Tumor antigens are known to be poorly immunogenic and attempts to elicit immune responses against the antigens specific to tumor cells have been largely unsuccessful. The inventors have developed a cancer vaccine comprising a defensin peptide fused to a tumor antigen to enhance the immunogenicity of the tumor antigen. The inventors have demonstrated in an animal model that chimeric defensing proteins fused to a lymphoma antigen generate a measurable anti-tumor cellular immune response.

Potential Commercial Applications: Competitive Advantages:
A vaccine for increasing the immunogenicity of a tumor antigen, allowing the treatment of cancer.   Can produce an in vivo immune response, resulting in the inhibition of tumor cells.

Bira Arya (NCI)
Larry Kwak (NCI)

Intellectual Property:
US Application No. 10/380,926
US Application No. 12/786,334
US Application No. 13/019,160
US Application No. 13/303,081
US Application No. 60/233,074
US Application No. 14/021,898
PCT Application No. PCT/US01/29074
US Application No. 14/268,949

Collaboration Opportunity:

The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize cancer vaccines comprising a defensin fused to tumor or viral antigens. For collaboration opportunities, please contact Nicole Guyton, Ph.D. at 301-435-3101 or for more information. Click here to view the NCI collaborative opportunity announcement.

Licensing Contact:
Yolanda Hawkins , Ph.D.
NIH Office of Technology Transfer
Phone: 301-435-5170

OTT Reference No: E-196-2000/0

Updated: Oct-26-2012